Digital Science is pleased to share some big Labguru news!

Today, Labguru announces that the Innovative Medicines unit of AstraZeneca, the global pharmaceutical business, has adopted Labguru’s research and lab management system for the global management of biological reagents used in pre-clinical research.

Scientists will use the Labguru platform across multiple AstraZeneca sites in North America and Europe, replacing and consolidating several legacy systems spanning several scientific disciplines. Labguru’s modular web-based system offers an easy means of tracking projects, protocols, biological collections and materials, as well as streamlining collaboration between members of the lab and between institutions.

Louis Culot, Chief Executive Officer of BioData, the company behind Labguru, adds:

“AstraZeneca selected Labguru after a rigorous assessment of their needs and available solutions. Our approach comprising an integrated scientific research platform that currently enables multi-site academic collaboration, is resulting in measurable improvements in laboratory management, scientific reproducibility, and transparency. We look forward to supporting AstraZeneca’s vision of delivering life-changing medicines to patients.” 

Lorenz Mayr, VP of Reagents and Assay Development at AstraZeneca says:

“We conducted a comprehensive evaluation and found Labguru to be the most suitable solution for the management of our global preclinical biological reagents. BioData’s experience with supporting academic groups, together with the cloud-based Labguru installation, will allow AstraZeneca scientists greater opportunities to share our biological research reagents with future external partners, to support new drug discovery projects for which there is currently an unmet medical need.”

If you want to find out more about Labguru, including news like this, you can check out their blog here and follow them on Twitter, they’re @Labguru.